{"id":521908,"date":"2021-08-03T07:03:48","date_gmt":"2021-08-03T11:03:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/"},"modified":"2021-08-03T07:03:48","modified_gmt":"2021-08-03T11:03:48","slug":"cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/","title":{"rendered":"Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update"},"content":{"rendered":"<h2>\nCyclacel will also participate in the BTIG Virtual Biotechnology Conference<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">BERKELEY HEIGHTS, N.J., Aug.  03, 2021  (GLOBE NEWSWIRE) &#8212; Cyclacel Pharmaceuticals, Inc.\u00a0(NASDAQ: CYCC, NASDAQ: CYCCP; &#8220;Cyclacel&#8221; or the &#8220;Company&#8221;), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter financial results and provide a business update on\u00a0Wednesday, August 11, 2021. The company will host a conference call and live webcast at\u00a04:30 p.m. Eastern Daylight Time\u00a0on the same day.<\/p>\n<p>\n        <strong>Conference call information:<\/strong>\n      <\/p>\n<p>\n        <strong>Conference ID: CYCCQ221<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>US\u00a0call: (866) 342-8591\/ international call: +1 (203) 518-9713\u00a0<\/p>\n<p>Replay: US: (800) 839-5109 \/ international archive: +1 (402) 220-2688<\/p>\n<p>Code for live and replay conference call is CYCCQ221 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s1N_bDrywNXeGKjQ_-LrbQptA_spsl0JBeZlwOZIeeU8UiAoCmFNDxPX9hVXFNKwx2sWHJqDgRJBcSWbeO9-Gd2S-9A2ZNmMDUyfPIBLMeFEvjod2qsFu2MbH-BVMa48v8xGNtUTei1LRf6X-FoLxw==\" rel=\"nofollow noopener\" target=\"_blank\">Webcast link<\/a>.<\/p>\n<p>For the live and replay webcast, please visit the Corporate Presentations page on the\u00a0Cyclacel\u00a0website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wEiFL-gzQQpCT-ARbahV_eOuYvuE_l50HteuAFX-JcloRRc1A8gXbk_CQmroCU2CAoGy46PszE1dtbJeRHB98g==\" rel=\"nofollow noopener\" target=\"_blank\">www.cyclacel.com<\/a>.<\/p>\n<p>\n        <strong>BTIG Virtual Biotechnology Conference, August 9, 2021<\/strong><br \/>\n        <br \/>Fireside chat at 9:00 am EDT<\/p>\n<p>\n        <strong>About Cyclacel Pharmaceuticals, Inc.<\/strong>\n      <\/p>\n<p>Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2\/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies.\u00a0Cyclacel&#8217;s\u00a0strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wEiFL-gzQQpCT-ARbahV_YjsCh-YBJb_IZl6_0y-FacCfutDDuHZtnxTbWJt98to2idHujupjMSzRvmOjAfNFA==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.cyclacel.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Forward-looking Statements<\/strong>\n      <\/p>\n<p>This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel&#8217;s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and\/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;potential,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;continues,&#8221; &#8220;forecast,&#8221; &#8220;designed,&#8221; &#8220;goal,&#8221; or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GvTGX0bGchMLCW_H3ZuWPZPoJEgWVS3J3mJU4FUXdmV-p5xldizAKVuwpWH7PFKkTvt8HGNrsBkBeHAqTxzYCA==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.sec.gov<\/u><\/a>. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">\n            <strong>Contacts<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Company:\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle\">Paul McBarron, (908) 517-7330, <a href=\"mailto:pmcbarron@cyclacel.com\" rel=\"nofollow noopener\" target=\"_blank\">pmcbarron@cyclacel.com<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Investor Relations:\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle\">LifeSci Advisors, LLC, Irina Koffler, (646) 970-4681, <a href=\"mailto:ikoffler@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">ikoffler@lifesciadvisors.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p>\u00a9 Copyright 2021 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel\u00ae are trademarks of Cyclacel.<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTYyOSM0MzM4MDYxIzIwMDY3NDE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/18f038c2-1b85-4035-bca6-a228b1f7f5d1\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cyclacel will also participate in the BTIG Virtual Biotechnology Conference BERKELEY HEIGHTS, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) &#8212; Cyclacel Pharmaceuticals, Inc.\u00a0(NASDAQ: CYCC, NASDAQ: CYCCP; &#8220;Cyclacel&#8221; or the &#8220;Company&#8221;), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter financial results and provide a business update on\u00a0Wednesday, August 11, 2021. The company will host a conference call and live webcast at\u00a04:30 p.m. Eastern Daylight Time\u00a0on the same day. Conference call information: Conference ID: CYCCQ221\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 US\u00a0call: (866) 342-8591\/ international call: +1 (203) 518-9713\u00a0 Replay: US: (800) 839-5109 \/ international archive: +1 (402) 220-2688 Code for live and replay conference call is CYCCQ221 Webcast link. For the live and replay webcast, please visit the Corporate Presentations page &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-521908","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cyclacel will also participate in the BTIG Virtual Biotechnology Conference BERKELEY HEIGHTS, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) &#8212; Cyclacel Pharmaceuticals, Inc.\u00a0(NASDAQ: CYCC, NASDAQ: CYCCP; &#8220;Cyclacel&#8221; or the &#8220;Company&#8221;), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter financial results and provide a business update on\u00a0Wednesday, August 11, 2021. The company will host a conference call and live webcast at\u00a04:30 p.m. Eastern Daylight Time\u00a0on the same day. Conference call information: Conference ID: CYCCQ221\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 US\u00a0call: (866) 342-8591\/ international call: +1 (203) 518-9713\u00a0 Replay: US: (800) 839-5109 \/ international archive: +1 (402) 220-2688 Code for live and replay conference call is CYCCQ221 Webcast link. For the live and replay webcast, please visit the Corporate Presentations page &hellip; Continue reading &quot;Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-03T11:03:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTYyOSM0MzM4MDYxIzIwMDY3NDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update\",\"datePublished\":\"2021-08-03T11:03:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\\\/\"},\"wordCount\":544,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTYyOSM0MzM4MDYxIzIwMDY3NDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\\\/\",\"name\":\"Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTYyOSM0MzM4MDYxIzIwMDY3NDE=\",\"datePublished\":\"2021-08-03T11:03:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTYyOSM0MzM4MDYxIzIwMDY3NDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTYyOSM0MzM4MDYxIzIwMDY3NDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/","og_locale":"en_US","og_type":"article","og_title":"Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update - Market Newsdesk","og_description":"Cyclacel will also participate in the BTIG Virtual Biotechnology Conference BERKELEY HEIGHTS, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) &#8212; Cyclacel Pharmaceuticals, Inc.\u00a0(NASDAQ: CYCC, NASDAQ: CYCCP; &#8220;Cyclacel&#8221; or the &#8220;Company&#8221;), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter financial results and provide a business update on\u00a0Wednesday, August 11, 2021. The company will host a conference call and live webcast at\u00a04:30 p.m. Eastern Daylight Time\u00a0on the same day. Conference call information: Conference ID: CYCCQ221\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 US\u00a0call: (866) 342-8591\/ international call: +1 (203) 518-9713\u00a0 Replay: US: (800) 839-5109 \/ international archive: +1 (402) 220-2688 Code for live and replay conference call is CYCCQ221 Webcast link. For the live and replay webcast, please visit the Corporate Presentations page &hellip; Continue reading \"Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-03T11:03:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTYyOSM0MzM4MDYxIzIwMDY3NDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update","datePublished":"2021-08-03T11:03:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/"},"wordCount":544,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTYyOSM0MzM4MDYxIzIwMDY3NDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/","name":"Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTYyOSM0MzM4MDYxIzIwMDY3NDE=","datePublished":"2021-08-03T11:03:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTYyOSM0MzM4MDYxIzIwMDY3NDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTYyOSM0MzM4MDYxIzIwMDY3NDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide-business-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=521908"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521908\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=521908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=521908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=521908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}